Stroke Risk as a Function of Atrial Fibrillation Duration and CHA2DS2-VASc Score
- PMID: 31564126
- DOI: 10.1161/CIRCULATIONAHA.119.041303
Stroke Risk as a Function of Atrial Fibrillation Duration and CHA2DS2-VASc Score
Abstract
Background: Studies of patients with cardiovascular implantable electronic devices show a relationship between atrial fibrillation (AF) duration and stroke risk, although the interaction with CHA2DS2-VASc score is poorly defined. The objective of this study is to evaluate rates of stroke and systemic embolism (SSE) in patients with cardiovascular implantable electronic devices as a function of both CHA2DS2-VASc score and AF duration.
Methods: Data from the Optum electronic health record deidentified database (2007-2017) were linked to the Medtronic CareLink database of cardiovascular implantable electronic devices capable of continuous AF monitoring. An index date was assigned as the later of either 6 months after device implantation or 1 year after electronic health record data availability. CHA2DS2-VASc score was assessed using electronic health record data before the index date. Maximum daily AF burden (no AF, 6 minutes-23.5 hours, and >23.5 hours) was assessed over the 6 months before the index date. SSE rates were computed after the index date.
Results: Among 21 768 nonanticoagulated patients with cardiovascular implantable electronic devices (age, 68.6±12.7 years; 63% male), both increasing AF duration (P<0.001) and increasing CHA2DS2-VASc score (P<0.001) were significantly associated with annualized risk of SSE. SSE rates were low in patients with a CHA2DS2-VASc score of 0 to 1 regardless of device-detected AF duration. However, stroke risk crossed an actionable threshold defined as >1%/y in patients with a CHA2DS2-VASc score of 2 with >23.5 hours of AF, those with a CHA2DS2-VASc score of 3 to 4 with >6 minutes of AF, and patients with a CHA2DS2-VASc score ≥5 even with no AF.
Conclusions: There is an interaction between AF duration and CHA2DS2-VASc score that can further risk-stratify patients with AF for SSE and may be useful in guiding anticoagulation therapy.
Keywords: atrial fibrillation; pacemaker, artificial; stroke.
Comment in
-
Letter by Cao et al Regarding Article, "Stroke Risk as a Function of Atrial Fibrillation Duration and CHA2DS2-VASc Score".Circulation. 2020 Mar 10;141(10):e597-e598. doi: 10.1161/CIRCULATIONAHA.119.044621. Epub 2020 Mar 9. Circulation. 2020. PMID: 32150473 No abstract available.
-
Response by Kaplan et al to Letter Regarding Article, "Stroke Risk as a Function of Atrial Fibrillation Duration and CHA2DS2-VASc Score".Circulation. 2020 Mar 10;141(10):e599-e600. doi: 10.1161/CIRCULATIONAHA.120.045850. Epub 2020 Mar 9. Circulation. 2020. PMID: 32150474 No abstract available.
Similar articles
-
Use of Oral Anticoagulation in a Real-World Population With Device Detected Atrial Fibrillation.J Am Heart Assoc. 2020 Dec 15;9(24):e018378. doi: 10.1161/JAHA.120.018378. Epub 2020 Nov 30. J Am Heart Assoc. 2020. PMID: 33252286 Free PMC article.
-
The Value of the CHADS2 and CHA2DS2-VASc Score for Predicting the Prognosis in Lacunar Stroke with or without Atrial Fibrillation Patients.J Stroke Cerebrovasc Dis. 2019 Nov;28(11):104143. doi: 10.1016/j.jstrokecerebrovasdis.2019.03.027. Epub 2019 Aug 30. J Stroke Cerebrovasc Dis. 2019. PMID: 31477449
-
Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.Cerebrovasc Dis. 2013;36(4):273-80. doi: 10.1159/000353670. Epub 2013 Oct 16. Cerebrovasc Dis. 2013. PMID: 24135809
-
Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.Tex Heart Inst J. 2015 Feb 1;42(1):6-15. doi: 10.14503/THIJ-14-4353. eCollection 2015 Feb. Tex Heart Inst J. 2015. PMID: 25873792 Free PMC article. Review.
-
Stroke Risk in Atrial Fibrillation: Beyond the CHA2DS2-VASc Score.Curr Cardiol Rep. 2019 Jul 27;21(9):95. doi: 10.1007/s11886-019-1189-6. Curr Cardiol Rep. 2019. PMID: 31352536 Review.
Cited by
-
Performance of Ambulatory Electrocardiographic Data for Prediction of Stroke and Heart Failure Events.JACC Adv. 2024 Oct 18;3(11):101340. doi: 10.1016/j.jacadv.2024.101340. eCollection 2024 Nov. JACC Adv. 2024. PMID: 39497946 Free PMC article.
-
Using Atrial Fibrillation Burden Trends and Machine Learning to Predict Near-Term Risk of Cardiovascular Hospitalization.Circ Arrhythm Electrophysiol. 2024 Nov;17(11):e012991. doi: 10.1161/CIRCEP.124.012991. Epub 2024 Oct 24. Circ Arrhythm Electrophysiol. 2024. PMID: 39445440 Free PMC article.
-
Performance of Atrial Fibrillation Burden Trends for Stroke Risk Stratification.Circ Arrhythm Electrophysiol. 2024 Nov;17(11):e012394. doi: 10.1161/CIRCEP.123.012394. Epub 2024 Oct 24. Circ Arrhythm Electrophysiol. 2024. PMID: 39445430 Free PMC article.
-
Atrial High-Rate Episodes and Subclinical Atrial Fibrillation: State of the Art and Clinical Questions with Complex Solutions.Rev Cardiovasc Med. 2024 Aug 22;25(8):305. doi: 10.31083/j.rcm2508305. eCollection 2024 Aug. Rev Cardiovasc Med. 2024. PMID: 39228483 Free PMC article. Review.
-
Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: assessing net clinical benefit.Eur Heart J Suppl. 2024 Jul 31;26(Suppl 4):iv4-iv11. doi: 10.1093/eurheartjsupp/suae075. eCollection 2024 Jul. Eur Heart J Suppl. 2024. PMID: 39099575 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
